Targeted muscle reinnervation in prosthetic arms: Amputees' remaining arm muscles can be "reinnervated" to produce enough signals to control an artificial arm in real time, according to data from five patients treated at the Rehabilitation Institute of Chicago published in the Feb. 11 Journal of the American Medical Association. In the study, five people with shoulder disarticulation or transhumeral amputations underwent targeted muscle innervations; transfer of the remaining arm nerves to residual chest or upper-arm muscles transforms the muscles into "biological amplifiers" of motor commands from the transferred nerves. The target muscles produce electromyogram signals on the surface of the skin that can control an artificial elbow, wrist and hand, according to study author Todd A. Kuiken, M.D./Ph.D., Neural Engineering Center for Artificial Limbs, et al. The patients in the study were able to repeatedly perform 10 different elbow, wrist and hand motions with their artificial arm. The mean motion selection and motion completion times for elbow and wrist movements were 0.22 seconds and 1.29 seconds, respectively. These times were only 0.06 seconds and 0.21 seconds longer than the mean time for five non-amputee patients enrolled as the control group. In an accompanying editorial, Gerald E. Loeb, University of Southern California's Departments of Biomechanical Engineering and Neurology, calls Kuiken's results "exciting and promising." Loeb adds: "Such revolutions develop slowly at best, but their effects tend to be profound. With increasing functional capabilities, patients with upper-extremity amputations may derive exceptional benefit from prosthetic arms, just as legions of patients with lower-extremity amputations now lead remarkably normal and even athletic lives.
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.
German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.
Medtronic expects operating profit to grow approximately 7% in fiscal 2026, excluding tariff impacts. If tariffs materialize at the upper end of the projected range, operating profit growth could drop by 2.2 to 3.2 percentage points.
